Farshad Mirzavi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Farshad Mirzavi has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Soukhtanloo
Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran
5 shared publications - Mohammad Jalili-Nik
Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4 shared publications - Amir Reza Afshari
Department of Basic Sciences, Faculty of Medicine, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran
3 shared publications - Ahmad Ghorbani
Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication Amin Reza Nikpoor
Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
1 shared publicationAnvar Soleimani
Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication
Latest Publications
- Open Access
- 1 June 2026
- Published by InkVista Publishing House
- Vol. 33 (1) , 1-5
Together for Health, Stand with Science: A Decade of Global Health Discourse on World Health Day
In recent years, World Health Day has evolved from a purely symbolic occasion to a platform for highlighting the most important global health challenges and guiding policy priorities. The theme for 2026, "Together for Health, Stand with Science," emphasizes the importance of collective action and evidence-based decision-making in the face of complex ...
- 1 June 2026
- Published by InkVista Publishing House
- Vol. 33 (1) , 1-5
Open AccessTogether for Health, Stand with Science: A Decade of Global Health Discourse on World Health Day
In recent years, World Health Day has evolved from a purely symbolic occasion to a platform for highlighting the most important global health challenges and guiding policy priorities. The theme for 2026, "Together for Health, Stand with Science," emphasizes the importance of collective action and evidence-based decision-making in the face of complex ...
- 12 November 2025
- Published by Wiley in BioFactors
- Vol. 51 (6) , e70053
A Comprehensive Insight Into the Roles of Exosomal circRNAs in Metabolic Syndrome
Exosomes are nano‐sized extracellular vesicles that contain specific proteins, nucleic acids, and lipids. These small vesicles are significant in a wide range of physiological and pathological conditions. Circular RNAs (circRNAs) are a subclass of noncoding RNAs that are expressed differently in many tissues and play essential roles in biological function. circRNAs are remarkably stable and prevalent in exosomes. These properties make them ideal candidates for biomedical research. Exosomal circRNAs function as pathogenic regulators, biomarkers, and therapy candidates in various diseases, including metabolic syndrome. Metabolic syndrome is a multifaceted condition distinguished by disruptions in the body's metabolism, encompassing obesity, insulin resistance, diabetes, nonalcoholic fatty liver disease, hyperlipidemia, and atherosclerosis. This syndrome is linked to a high risk of type 2 diabetes, cardiovascular disease, cancer, and mortality. In this review, we provide a comprehensive overview of the roles of exosomal circRNAs in metabolic syndrome, providing recent perspectives on the pathogenesis, diagnosis, and treatment of these complicated disorders.
- 12 November 2025
- Published by Wiley in BioFactors
- Vol. 51 (6) , e70053
A Comprehensive Insight Into the Roles of Exosomal circRNAs in Metabolic Syndrome
Exosomes are nano‐sized extracellular vesicles that contain specific proteins, nucleic acids, and lipids. These small vesicles are significant in a wide range of physiological and pathological conditions. Circular RNAs (circRNAs) are a subclass of noncoding RNAs that are expressed differently in many tissues and play essential roles in biological function. circRNAs are remarkably stable and prevalent in exosomes. These properties make them ideal candidates for biomedical research. Exosomal circRNAs function as pathogenic regulators, biomarkers, and therapy candidates in various diseases, including metabolic syndrome. Metabolic syndrome is a multifaceted condition distinguished by disruptions in the body's metabolism, encompassing obesity, insulin resistance, diabetes, nonalcoholic fatty liver disease, hyperlipidemia, and atherosclerosis. This syndrome is linked to a high risk of type 2 diabetes, cardiovascular disease, cancer, and mortality. In this review, we provide a comprehensive overview of the roles of exosomal circRNAs in metabolic syndrome, providing recent perspectives on the pathogenesis, diagnosis, and treatment of these complicated disorders.
- Open Access
- 17 November 2023
- Published by Sociedade Brasileira de Cardiologia in International Journal of Cardiovascular Sciences
- Vol. 36
miR-27a/b Level is Associated with ABCA1 Expression and is a Potential PBMC-Based Biomarker for Coronary Artery Disease
Background: Coronary artery disease (CAD) is the most common form of cardiac disease with high morbidity and mortality rates. Objectives: In this study, we evaluated the expression of miR-27a and miR-27b as biomarkers in peripheral blood mononuclear cells (PBMCs) of patients with CAD and investigated its correlation with cholesterol-efflux transporter, ATP-binding cassette transporter A1 (ABCA1). Method: This study was performed on 54 men with CAD and 51 healthy, sex- and age-matched control participants. The expression of miR-27a/b and ABCA1 [...] Abstract Background: Coronary artery disease (CAD) is the most common form of cardiac disease with high morbidity and mortality rates. Objectives: In this study, we evaluated the expression of miR-27a and miR-27b as biomarkers in peripheral blood mononuclear cells (PBMCs) of patients with CAD and investigated its correlation with cholesterol-efflux transporter, ATP-binding cassette transporter A1 (ABCA1). Method: This study was performed on 54 men with CAD and 51 healthy, sex- and age-matched control participants. The expression of miR-27a/b and ABCA1
- 17 November 2023
- Published by Sociedade Brasileira de Cardiologia in International Journal of Cardiovascular Sciences
- Vol. 36
Open AccessmiR-27a/b Level is Associated with ABCA1 Expression and is a Potential PBMC-Based Biomarker for Coronary Artery Disease
Background: Coronary artery disease (CAD) is the most common form of cardiac disease with high morbidity and mortality rates. Objectives: In this study, we evaluated the expression of miR-27a and miR-27b as biomarkers in peripheral blood mononuclear cells (PBMCs) of patients with CAD and investigated its correlation with cholesterol-efflux transporter, ATP-binding cassette transporter A1 (ABCA1). Method: This study was performed on 54 men with CAD and 51 healthy, sex- and age-matched control participants. The expression of miR-27a/b and ABCA1 [...] Abstract Background: Coronary artery disease (CAD) is the most common form of cardiac disease with high morbidity and mortality rates. Objectives: In this study, we evaluated the expression of miR-27a and miR-27b as biomarkers in peripheral blood mononuclear cells (PBMCs) of patients with CAD and investigated its correlation with cholesterol-efflux transporter, ATP-binding cassette transporter A1 (ABCA1). Method: This study was performed on 54 men with CAD and 51 healthy, sex- and age-matched control participants. The expression of miR-27a/b and ABCA1
- 10 November 2023
- Published by Elsevier in Letters in Drug Design & Discovery
- Vol. 21 (15) , 3134-3148
Hepatoprotective Effects of Rheum turkestanicum Janisch on High-fat Diet-induced Non-alcoholic Fatty Liver Disease in Mice
Background: Consumption of a high-fat diet (HFD) is one of the main causes of nonalcoholic fatty liver disease (NAFLD), which is increasing due to lifestyle changes and is still an important global health issue. Despite the efforts, there is still no common treatment for this disease. Studies have shown that the root of Rheum turkestanicum Janisch has a hypolipidemic effect and a significant antioxidant effect on liver tissue in diabetic rats. However, no experimental study has been performed on the hepatoprotective effects of this herb on HFD-induced NAFLD have been proven. background: Consumption of a high-fat diet (HFD) is one of the main causes of non-alcoholic fatty liver disease (NAFLD), which is increasing due to lifestyle changes and is still an important global health issue. Despite the efforts, there is still no common treatment for this disease. Studies have shown that the root of Rheum turkestanicum Janisch has a hypolipidemic effect and a significant antioxidant effect on liver tissue in diabetic rats. However, no experimental study has been performed on which the hepatoprotective effects of this herb on HFD-induced NAFLD have been proven. Objective: This study aimed to evaluate the effect of Rheum turkestanicum Janisch extract (RTE) on HFD-induced NAFLD in BALB/c mice. Materials and Methods: The study was performed with two models of prevention and therapeutic effect of RTE. Serum biochemical markers, histopathology, oxidative stress indicators, and qRTPCR were measured to evaluate the effects of RTE on lipid metabolism disorders in mice feeding with HFD. Results: In the prevention model, compared to the HFD group, RTE treatment decreased the levels of glucose, triglyceride, and cholesterol and improved liver profile markers, oxidative stress, and expression of genes involved in lipid metabolism. Conclusion: The results of this study suggest that RTE has hepatoprotective effects against HFDinduced liver damage by reducing oxidative stress, lipogenesis, and increasing beta-oxidation of free fatty acids.
- 10 November 2023
- Published by Elsevier in Letters in Drug Design & Discovery
- Vol. 21 (15) , 3134-3148
Hepatoprotective Effects of Rheum turkestanicum Janisch on High-fat Diet-induced Non-alcoholic Fatty Liver Disease in Mice
Background: Consumption of a high-fat diet (HFD) is one of the main causes of nonalcoholic fatty liver disease (NAFLD), which is increasing due to lifestyle changes and is still an important global health issue. Despite the efforts, there is still no common treatment for this disease. Studies have shown that the root of Rheum turkestanicum Janisch has a hypolipidemic effect and a significant antioxidant effect on liver tissue in diabetic rats. However, no experimental study has been performed on the hepatoprotective effects of this herb on HFD-induced NAFLD have been proven. background: Consumption of a high-fat diet (HFD) is one of the main causes of non-alcoholic fatty liver disease (NAFLD), which is increasing due to lifestyle changes and is still an important global health issue. Despite the efforts, there is still no common treatment for this disease. Studies have shown that the root of Rheum turkestanicum Janisch has a hypolipidemic effect and a significant antioxidant effect on liver tissue in diabetic rats. However, no experimental study has been performed on which the hepatoprotective effects of this herb on HFD-induced NAFLD have been proven. Objective: This study aimed to evaluate the effect of Rheum turkestanicum Janisch extract (RTE) on HFD-induced NAFLD in BALB/c mice. Materials and Methods: The study was performed with two models of prevention and therapeutic effect of RTE. Serum biochemical markers, histopathology, oxidative stress indicators, and qRTPCR were measured to evaluate the effects of RTE on lipid metabolism disorders in mice feeding with HFD. Results: In the prevention model, compared to the HFD group, RTE treatment decreased the levels of glucose, triglyceride, and cholesterol and improved liver profile markers, oxidative stress, and expression of genes involved in lipid metabolism. Conclusion: The results of this study suggest that RTE has hepatoprotective effects against HFDinduced liver damage by reducing oxidative stress, lipogenesis, and increasing beta-oxidation of free fatty acids.
- 28 August 2023
- Published by Springer Nature in Journal of Nanoparticle Research
- Vol. 25 (9) , 1-14
Protective effect of hesperidin-loaded selenium nanoparticles stabilized by chitosan on glutamate-induced toxicity in PC12 cells
- 28 August 2023
- Published by Springer Nature in Journal of Nanoparticle Research
- Vol. 25 (9) , 1-14
Protective effect of hesperidin-loaded selenium nanoparticles stabilized by chitosan on glutamate-induced toxicity in PC12 cells
- 13 August 2023
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 33 (6) , 1177-1186
Combination of Alpha-Lipoic Acid and Auraptene Induces Apoptosis and Prevents Proliferation of the Human U-87 Glioblastoma Cells
- 13 August 2023
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 33 (6) , 1177-1186
Combination of Alpha-Lipoic Acid and Auraptene Induces Apoptosis and Prevents Proliferation of the Human U-87 Glioblastoma Cells
- 22 December 2022
- Published by SAGE Publications in Alternatives to Laboratory Animals
- Vol. 51 (1) , 30-38
The Effects of Urolithin B and Auraptene on Quinolinic Acid-induced Toxicity in the SH-SY5Y Neuroblastoma Cell Line
The pathological accumulation of quinolinic acid (QA) is often associated with neuritis and neuronal cell death in several neurodegenerative diseases, through the overproduction of free radicals. Urolithin B and auraptene have been reported to exert potent antioxidant effects — however, little is known about the protective effects of these compounds against QA-induced neurotoxicity. Therefore, this study aimed to explore the in vitro protective effects of urolithin B and auraptene against QA-induced neurotoxicity in the SH-SY5Y neuroblastoma cell line. The MTT assay was used to evaluate cell viability, and flow cytometry was carried out to evaluate effects on the cell cycle and apoptosis. The intracellular levels of reactive oxygen species (ROS) were also determined. Our findings showed that auraptene at non-toxic concentrations had no protective effect on QA-induced toxicity. However, urolithin B at concentrations of 0.6 μM and 2.5 μM enhanced the viability of cells treated with QA. Moreover, while the percentage of apoptotic cells (i.e. in the sub-G1 phase) was shown to significantly increase after QA treatment, pre-treatment with urolithin B reduced the number of these apoptotic cells. Furthermore, urolithin B, as an antioxidant, also significantly reduced QA-induced ROS production. Our findings suggest that urolithin B may possess potent antioxidant and neuroprotective effects against QA-induced neurotoxicity that merit further investigation.
- 22 December 2022
- Published by SAGE Publications in Alternatives to Laboratory Animals
- Vol. 51 (1) , 30-38
The Effects of Urolithin B and Auraptene on Quinolinic Acid-induced Toxicity in the SH-SY5Y Neuroblastoma Cell Line
The pathological accumulation of quinolinic acid (QA) is often associated with neuritis and neuronal cell death in several neurodegenerative diseases, through the overproduction of free radicals. Urolithin B and auraptene have been reported to exert potent antioxidant effects — however, little is known about the protective effects of these compounds against QA-induced neurotoxicity. Therefore, this study aimed to explore the in vitro protective effects of urolithin B and auraptene against QA-induced neurotoxicity in the SH-SY5Y neuroblastoma cell line. The MTT assay was used to evaluate cell viability, and flow cytometry was carried out to evaluate effects on the cell cycle and apoptosis. The intracellular levels of reactive oxygen species (ROS) were also determined. Our findings showed that auraptene at non-toxic concentrations had no protective effect on QA-induced toxicity. However, urolithin B at concentrations of 0.6 μM and 2.5 μM enhanced the viability of cells treated with QA. Moreover, while the percentage of apoptotic cells (i.e. in the sub-G1 phase) was shown to significantly increase after QA treatment, pre-treatment with urolithin B reduced the number of these apoptotic cells. Furthermore, urolithin B, as an antioxidant, also significantly reduced QA-induced ROS production. Our findings suggest that urolithin B may possess potent antioxidant and neuroprotective effects against QA-induced neurotoxicity that merit further investigation.
- 24 August 2022
- Published by Springer Nature in Biologia
- Vol. 77 (12) , 3595-3602
Bee venom induces anti-tumor effects in HT-29 colon cancer cells through regulation of cell proliferation and apoptosis
- 24 August 2022
- Published by Springer Nature in Biologia
- Vol. 77 (12) , 3595-3602
Bee venom induces anti-tumor effects in HT-29 colon cancer cells through regulation of cell proliferation and apoptosis
- 2 August 2021
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 29 (6) , 814-824
Enhanced antitumor immune response in melanoma tumor model by anti-PD-1 small interference RNA encapsulated in nanoliposomes
Programmed cell death protein-1 (PD-1), as an immune checkpoint molecule, attenuates T-cell activity and induces T-cell exhaustion. Although siRNA has a great potential in cancer immunotherapy, its delivery to target cells is the main limitation of using siRNA. This study aimed to prepare a liposomal formulation as a siRNA carrier to silence PD-1 expression in T cells and investigate it’s in vivo antitumor efficacy. The liposomal siRNA was prepared and characterized by size, zeta potential, and biodistribution. Following that, the uptake assay and mRNA silencing were evaluated in vitro at mRNA and protein levels. siRNA-PD-1 (siPD-1)-loaded liposome nanoparticles were injected into B16F0 tumor-bearing mice to evaluate tumor growth, tumor-infiltrating lymphocytes, and survival rate. Liposomal siPD-1 efficiently silenced PD-1 mRNA expression in T cells (P < 0.0001), and siPD-1-loaded liposomal nanoparticles enhanced the infiltration of T-helper 1 (Th 1) and cytotoxic T lymphocytes into the tumor tissue (P < 0.0001). Liposome-PD-1 siRNA monotherapy and PD-1 siRNA-Doxil (liposomal doxorubicin) combination therapy improved the survival significantly, compared to the control treatment (P < 0.001). Overall, these findings suggest that immunotherapy with siPD-1-loaded liposomes by enhancing T-cell-mediated antitumor immune responses could be considered as a promising strategy for the treatment of melanoma cancer.
- 2 August 2021
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 29 (6) , 814-824
Enhanced antitumor immune response in melanoma tumor model by anti-PD-1 small interference RNA encapsulated in nanoliposomes
Programmed cell death protein-1 (PD-1), as an immune checkpoint molecule, attenuates T-cell activity and induces T-cell exhaustion. Although siRNA has a great potential in cancer immunotherapy, its delivery to target cells is the main limitation of using siRNA. This study aimed to prepare a liposomal formulation as a siRNA carrier to silence PD-1 expression in T cells and investigate it’s in vivo antitumor efficacy. The liposomal siRNA was prepared and characterized by size, zeta potential, and biodistribution. Following that, the uptake assay and mRNA silencing were evaluated in vitro at mRNA and protein levels. siRNA-PD-1 (siPD-1)-loaded liposome nanoparticles were injected into B16F0 tumor-bearing mice to evaluate tumor growth, tumor-infiltrating lymphocytes, and survival rate. Liposomal siPD-1 efficiently silenced PD-1 mRNA expression in T cells (P < 0.0001), and siPD-1-loaded liposomal nanoparticles enhanced the infiltration of T-helper 1 (Th 1) and cytotoxic T lymphocytes into the tumor tissue (P < 0.0001). Liposome-PD-1 siRNA monotherapy and PD-1 siRNA-Doxil (liposomal doxorubicin) combination therapy improved the survival significantly, compared to the control treatment (P < 0.001). Overall, these findings suggest that immunotherapy with siPD-1-loaded liposomes by enhancing T-cell-mediated antitumor immune responses could be considered as a promising strategy for the treatment of melanoma cancer.